| Wall Street Journal. Europe 2000 Stephen D. Moore |
| Title | Subject | Authors |
|---|
| AstraZeneca, Aventis Post Strong Drug Sales. Results at Firms' Agrochemical Units Contrast. | Business, international | Stephen D. Moore |
| AstraZeneca sells herbicide business to Dow Chemical. | Business, international | Stephen D. Moore |
| AstraZeneca shares decline 7.5% despite solid results, rosy outlook. | Business, international | Stephen D. Moore |
| AstraZeneca shares fall 2.5% after cutting sales outlook. | Business, international | Stephen D. Moore |
| Aventis boosts its forecast for year on strength in quarter. | Business, international | Stephen D. Moore |
| Aventis intends to divest its crop-protection division. | Business, international | Stephen D. Moore |
| Aventis to sell research center in France to subsidiary of DuPont. | Business, international | Stephen D. Moore |
| BASF beats out competition to buy Cyanamid of U.S. | Business, international | Stephen D. Moore, Nikhil Deogun |
| BASF Hopes U.S. Listing Will Boost Sagging Valuation.(Brief Article)(Statistical Data Included) | Business, international | Stephen D. Moore |
| BASF moves closer to Cyanamid deal. | Business, international | Stephen D. Moore, Nikhil Deogun, Robert Langreth |
| BASF to relocate pharmaceutical unit. | Business, international | Stephen D. Moore |
| Bayer enters pact to expand research.(joint venture with Exelixis Pharmaceuticals Inc. to form Genoptera L.L.C., agro-chemical research company) | Business, international | Stephen D. Moore |
| Chief steps down in shake-up at Transgene. | Business, international | Stephen D. Moore |
| Clariant nears a deal to buy BTP. | Business, international | Stephen D. Moore, Anita Raghavan |
| Deode genetics plans units for cancer, pharmacogenomics. | Business, international | Stephen D. Moore |
| Ebner plans to resign as BZ Bank president. | Business, international | Stephen D. Moore, G. Thomas Sims |
| European patients fight for access to cancer drugs. | Business, international | Stephen D. Moore |
| For Glaxo SmithKline, getting to the altar was just a beginning. | Business, international | Stephen D. Moore |
| Gemini's research targets twins.(Gemini Genomics PLC)(Statistical Data Included) | Business, international | Stephen D. Moore |
| Genset appoits Pernet as new chief executive.(Brief Article) | Business, international | Stephen D. Moore |
| Germany's BASF says net income jumped 82% in fourth quarter. | Business, international | Stephen D. Moore |
| Glaxo, SmithKline are likely to keep a tight lid on details of merger plan. | Business, international | Stephen D. Moore |
| Glaxo, SmithKline push back merger date by one month. | Business, international | Stephen D. Moore |
| Glaxo Wellcome's 1st-half net jumped 19% on strong sales. | Business, international | Stephen D. Moore |
| Newest ulcer drug from AstraZeneca has a slight edge.(New Nexium drug slightly better than the older version.)(Brief Article)(Statistical Data Included) | Business, international | Stephen D. Moore, Gardiner Harris |
| Novartis 11% profit increase, full-year results beat expectations. | Business, international | Stephen D. Moore |
| Novartis nears U.S. listing that could ease a merger. | Business, international | Stephen D. Moore, Robert Langreth |
| Novartis, Quaker Oats plan venture. | Business, international | Stephen D. Moore, Jonathan Eig |
| Novartis's new marker-gene system targets genetically modified crops.(Company hopes product will lessen fears of transgenic plants.)(Brief Article)(Statistical Data Included) | Business, international | Stephen D. Moore |
| Novartis unveils restructuring of its main drug division. | Business, international | Stephen D. Moore |
| Novo Nordisk cuts its voting interest in Seattle biotech. | Business, international | Stephen D. Moore |
| Roche, Decode claim they located gene linked to Alzheimer disease (DeCode Genetics Inc., and Roche Holding AG). | Business, international | Stephen D. Moore |
| Roche earnings jump but shares sink. | Business, international | Stephen D. Moore |
| Roche's net rockets 31% on gains from Genentech sale. | Business, international | Stephen D. Moore |
| Sanofi outs operating chief Guerin (Sanofi Synthelabo SA's COO Herve Guerin). | Business, international | Stephen D. Moore |
| Sanofi-Synthelabo's Net Jumped 23% In Second Half, Underscoring Strength. | Business, international | Stephen D. Moore |
| Shares of Glaxo and SmithKline Slip Despite Upbeat Corporate News. | Business, international | Stephen D. Moore |
| U.K. urged to boost stem cell research.(Brief Article) | Business, international | Stephen D. Moore |
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
